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Cardiovascular disease (CVD) is the leading cause of death globally, representing 31% of
all global deaths. HIV and long term anti-retroviral therapy (ART) are risk factors for develop-
ment of CVD in populations of people living with HIV (PLHIV). CVD risk assessment tools
are currently being applied to SSA populations, but there are questions about accuracy as
well as implementation challenges of these tools in lower resource setting populations. We
aimed to assess the level of agreement between the various cardiovascular screening tools
(Data collection on Adverse effects of anti-HIV Drugs (D:A:D), Framingham risk score,
WHO risk score and The Atherosclerotic Cardiovascular Disease Score) when applied to
an HIV ART experienced population in Sub-Saharan Africa.
Methods
This study was undertaken in an Anti-Retroviral Long Term (ALT) Cohort of 1000 PLHIV in
care who have been on ART for at least 10 years in urban Uganda. A systematic review was
undertaken to find the most frequently used screening tools from SSA PLHIV populations;
these were applied to the ALT cohort. Levels of agreement between the resulting scores
(those including lipids and non-lipids based, as well as HIV-specific and non-HIV specific)
as applied to our cohort were compared. Prevalence Bias Adjusted Kappa was used to eval-
uate agreement between tools.
Results
Overall, PLHIV in ALT cohort had a median score of 1.1–1.4% risk of a CVD event over 5
years and 1.7–2.5% risk of a CVD event over 10 years. There was no statistical difference in
PLOS ONE







Citation: Mubiru F, Castelnuovo B, Reynolds SJ,
Kiragga A, Tibakabikoba H, Owarwo NC, et al.
(2021) Comparison of different cardiovascular risk
tools used in HIV patient cohorts in sub-Saharan
Africa; do we need to include laboratory tests?
PLoS ONE 16(1): e0243552. https://doi.org/
10.1371/journal.pone.0243552
Editor: Kwasi Torpey, University of Ghana College
of Health Sciences, GHANA
Received: April 10, 2020
Accepted: November 23, 2020
Published: January 28, 2021
Copyright: © 2021 Mubiru et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: The relevant analysis
methods and results are all presented in the
submission. However, data cannot be shared
publicly because of confidentiality issues. Data are
available from the Infectious Diseases Institute(IDI)
In-house Data base - ICEA (The Integrated Clinic
Enterprise Application.). Access can be granted by
the research and Ethics Committee of the Joint
Clinical Research Centre(JCRC-Uganda) through
the Biostatistician, Infectious Diseases Institute,
College of Health Sciences, Makerere University,
the risk scores obtained for this population when comparing the different tools, including
comparisons of those with lipids and non-lipids, and HIV specific vs non-HIV specific.
Conclusion
The various tools yielded similar results, but those not including lipids are more feasible to
apply in our setting. Long-term cohorts of PLHIV in SSA should in future provide longitudinal
data to evaluate existing CVD risk prediction tools for these populations. Inclusion of HIV
and ART history factors to existing scoring systems may improve accuracy without adding
the expense and technical difficulty of lipid testing.
Introduction
Cardiovascular disease (CVD) is the leading cause of death globally. An estimated 17.9 million
people died from CVDs in 2016, representing 31% of all global deaths. Of these deaths, 85%
are due to Myocardial Infarction (MI) and Cerebrovascular Accidents (CVA). In Uganda spe-
cifically, a recent survey on Non Communicable Diseases (NCDs) by World Health Organisa-
tion (WHO) (2016), revealed that 10.5% of adults between 40–69 years have a 30% chance of
developing CVDs in the next 10 years [1]. However, unlike in high-income settings, screening
for cardio-vascular disease is not routinely undertaken.
The HIV infected population is estimated to be at 1.5–2 fold risk of death from CVD’s as
compared to the HIV negative population [2]. The likely pathogenic mechanisms are increased
vascular inflammation due to HIV virus circulation. However, there is also a risk attributed to
anti-retroviral (ARV) drugs, in part due to increased lipids, with some ARVs including abaca-
vir and protease inhibitors having stronger CVD risk as compared to other drugs [3]. Access
to anti-retroviral treatment (ART) has dramatically reduced mortality in people living with
HIV (PLHIV) in sub Saharan Africa (SSA) [4,5], but the experience with ART in SSA is shorter
(10–15 years) as compared to over 30 years’ experience in high income settings [6].
CVD screening tools such as the Framingham prediction model are based upon data col-
lected from large general population cohorts from high income settings [7]. These include fac-
tors such as age, sex, family history, weight, smoking, drug history and previous event history.
However, they also rely on availability of comprehensive laboratory test results such as lipid
profiles that are not widely available and are very costly in SSA. To counter this, the WHO and
others have devised screening tools that do not rely on inclusion of laboratory results. Addi-
tionally, some groups have worked to adapt these general population scores with factors spe-
cific to PLHIV (e.g. Data collection on Adverse effects of anti-HIV Drugs-D:A:D), accounting
for issues such as length and type of ART treatment history and renal function. These have
been found to be more sensitive and specific when being evaluated in a large population of
HIV positive patients [8]. However, these tests have not yet been evaluated on large SSA popu-
lations receiving ART.
As many PLHIV in SSA are now stable on ART for over a decade, with their HIV and ART
exposure as well as age is increasing [9], rolling out situationally appropriate screening for
CVD is becoming urgent and important. We established the Anti-retroviral Long Term (ALT)
Cohort of 1000 PLHIV receiving ART for at least 10 years at the Infectious Diseases Institute
(IDI), Kampala Uganda [10]. In this study we applied the most frequently used screening tools
for assessing CVD risk in PLHIV from SSA populations to our cohort. We then compared the
levels of agreement between the generated scores (those including lipids and non-lipids based,
as well as HIV-specific and non-HIV specific) as applied to our cohort.
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Methods
Review of tools used for cardio-vascular risk prediction by other cohorts in
sub-Saharan Africa
We performed a literature search (any paper ever published on CVD risk prediction in SSA as
of 31st/August 2018) on PubMed to identify primary articles on use of CVD risk screening in
SSA including PLHIV. We included all original research articles that reported on prediction
models, tools and scores that have been proposed for estimation of individual risk of any CVD
that have been used in SSA including general populations (including PLHIV) or exclusively
PLHIV populations. We excluded articles not written in English (or no translation available)
where we were unable to access the full text through a license at our institutes. The search
terms can be found in supplementary material.
Applying cardiovascular screening tools to the ART Long Term Cohort
study population
Between May 2014 and September 2015 we established the ART Long Term Cohort (ALT
cohort), a prospective observational cohort of 1000 adult patients previously on ART in their
consecutive 10th year of ART. The cohort has been described elsewhere [10]. Baseline and
annual visits include medical history, physical examination, CD4 count, viral load, and infor-
mation on ART and other co-medications information collected and entered into an elec-
tronic medical record (Integrated clinical Enterprise Application(ICEA [11]). Biological
samples (packed cells, plasma and serum) were stored at enrolment and follow-up visits; full
blood count, urea and electrolytes, as well as CD4, viral load and urine dipstick are done at
each visit. Participants receive a blood pressure check performed by a nurse, weight measured
using floor scales and BMI calculated in kgs/m2 calculation. Table 1 gives details on how risk
factors are ascertained within the IDI cohort. Lipid tests (Total Cholesterol, LDL, HDL and tri-
glycerides) were retrospectively performed (at Rakai Health Sciences Program laboratory) on
Table 1. Data evaluated for CVD risk evaluation in the ALT cohort.
Risk How evaluated Units of measurement
Hypertension
(systolic BP)




• On anti-hypertensive medication
>3 measurements
systolic >140 or diastolic >90
or
Recorded on EMR by diagnosis and medication
Body Mass Index Height and weight at entry to cohort
Weight in Kg / height2
Kg/m2
Diabetes 1) Self-reported
2) On diabetic medication
3) Diagnosed in clinic after abnormal blood glucose
EMR recorded diagnosis or medication
Glucose range? (4.0–6.0 mmol/l
Total cholesterol Roche Cobas chemistry analyzer machine Reference range (3.5 and 5.7 mmol/L)
Triglycerides Roche Cobas chemistry analyzer machine Reference range (0.10–10.00 mmol/L)
Total/HDL cholesterol levels Roche Cobas chemistry analyzer machine
Or reported hyperchoestrolaemia and on medication
Reference range (0.08–3.1 mmol/L)
EMR record of medication
Demographics Self-reported Age (years), sex
CD4 count baseline Facs Calibur machine Count recorded at entry into cohort
Anti-retroviral treatment exposure From ICEA records Drug exposure recorded on EMR
CVD—Cardiovascular Disease, IDI—Infectious Disease Institute, BP–Blood Pressure, EMR—Electronic Medical records, ICEA- Integrated Clinical Enterprise
Application.
https://doi.org/10.1371/journal.pone.0243552.t001
PLOS ONE Comparison of different cardiovascular risk tools used in HIV patient cohorts in sub-Saharan Africa
PLOS ONE | https://doi.org/10.1371/journal.pone.0243552 January 28, 2021 3 / 11
stored serum baseline samples. Hypertension is diagnosed by having either three or more con-
secutive systolic and diastolic Blood Pressure (BP) measurements above 140 and 90 respec-
tively, or self-reported, or being on antihypertensive drugs. Diabetes is evaluated from medical
history, glucose in urine followed by a plasma glucose analysis> 100mg/ml. Cardio-vascular
end points (CVA, MI and other e.g. valvular disease) at enrolment are self-reported.
Calculating absolute CVD risk scores using the CVD risk tools
Following the analysis of most commonly used tools in SSA, we used the most common tools
(summarized in supplementary Table 1 in S1 File) and applied them to the ALT cohort study
population enrolment visit data. These were then entered into a cross-classification table
showing the number of patients in each level of risk for each tool. Where there were variance
in model, we estimated the CVD risk for both the reduced (not including ART exposure data)
and the full model.
Comparison of these differing tools and resulting scores in our population
We summarised the generated scores using, medians for continuous variables, frequencies and
percentages for categorical variables. We used a Prevalence Bias Adjusted Kappa (PABAK) by
[12] equivalent to the weighted Brennan and Prediger [13] agreement coefficient for ordinal
scale ratings to assess the level of agreement of a given pair of the CVD risk tools in cross classi-
fying patients. A p-value of<0.05 was considered significant to assess levels of agreement.
Both the crude and PABAK and 95% confidence level are presented.
We undertook the following comparisons 1) lipids vs no lipids to see if it is possible to
screen without laboratory lipid evaluation 2) Inclusion or no inclusion of CVD family history.
There are both 5 and 10-year prediction scores. For 5- year and 10-year predictions, we used
D:A:D and ASCVD respectively as the main tools for the comparisons, as these are the scores
incorporating most parameters in the prediction. The levels of agreement between two scores
were assessed on the categories as per the set risk classification of the tools. The ASCVD tool
only allows for 2 levels of classification (low and moderate or high or very high). So for any
comparison of other scores with the ASCVD, re-classification of patient’s risk into these two
categories was done. Data management, generation of scores for the different tools and the
analysis was conducted using STATA Version 14.
Ethics. The ALT Cohort was approved by the research ethics committee of the Joint Clini-
cal Research Centre and was also approved by the Uganda National Council for Science and
Technology. The study is registered with Clinical trials.org (https://clinicaltrials.gov/) as ‘Out-
comes of HIV Infected Individuals after Ten Years on Antiretroviral Treatment’ Protocol
Record ST/0113/15. Our work adheres to the ‘Strengthening the Reporting of Observational
Studies in Epidemiology’ (STROBE) recommendations that provide guidance on the reporting
of cohort studies (described elsewhere [10]). All patients were sensitized about the study,
offered inclusion and written informed consent was sought at cohort enrollment by the cohort
nurse, counsellor or medical officer.
Results
Review of tools used for cardio-vascular risk prediction by other cohorts in
sub-Saharan Africa
Table 2 shows all ten studies we found in for screening in PLHIV in SSA; seven of these were
comparisons between different tools and 3 cross sectional screenings using one tool; seven
studies predicted 10-year risk, one predicted 5-year risk and two had a combination of five
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and ten years. Four studies incorporated HIV specific risks through use of the D:A:D score; all
of these were comparative studies. Only two studies incorporated World Health Organisation
/ International Society for Hypertension (WHO/ISH) blood tests sparing screening, all other
studies required laboratory blood test analyses of lipids. The most commonly used scores were
WHO/ISH CVD risk prediction charts [14], the Framingham Equation [15], the D:A:D and
the Framingham Equations calibrated to the D:A:D data [16,17] and the Pooled Cohort equa-
tion for Atherosclerotic Cardiovascular Disease (ASCVD) from the American College of Car-
diology/American Heart Association (ACC /AHA) [18].
Applying cardiovascular screening tools to the IDI cohort
Of the 1000 ALT cohort patients, a total of 966 patients were included in the analysis. Of the
34 that were excluded from this analysis, four were excluded for being above 75 years and 14
were missing lipid information. Sixteen had a history of CVD end points out of which 10
(62.5%) with a previous cerebro-vascular event (CVA) and 6 (37.5%) with various other car-
diovascular conditions including dilated Cardiomyopathy(DCM) (n = 2), pulmonary hyper-
tension (n = 2), valvular heart disease (n = 1), and arrhythmia (n = 1). The baseline
characteristics are presented in Table 3.
Table 2. Published work on CVD risk scores in sub-Saharan Africa.
Title Year Country Study populations Number of
patients
Scores used
Assessment of cardiovascular risk factors in people with HIV




HIV infected patients 214 Compared 10-year risk Framingham
(Lipids) equation and 5-year D:A:D
equation
Cardiovascular disease risk prediction by the American College of
Cardiology (ACC)/American Heart Association (AHA)
Atherosclerotic Cardiovascular Disease (ASCVD) risk score
among HIV-infected patients in sub-Saharan [20]
2017 Botswana HIV infected patients 208 10- years risk. Pooled Cohorts
Equation ASCVD and Framingham
(LIPIDS) equation
Relationship between estimated cardiovascular disease risk and
insulin resistance in a black African population living with HIV: a
cross-sectional study from Cameroon [21]
2017 Cameroon HIV infected patients 452 5-year risk by both Framingham
(Lipids) and the D:A:D CVD risk
equations
Dyslipidemia and cardiovascular disease risk profiles of patients
attending an HIV treatment clinic in Harare, Zimbabwe [22]
2015 Zimbabwe HIV infected patients 235 Framingham risk scores
High Prevalence of Metabolic Syndrome and Cardiovascular
Disease Risk Among People with HIV on Stable ART in South
western Uganda [23]
2016 Uganda HIV infected patients 271 Framingham risk score
Risk factors and assessment for cardiovascular disease among
HIV-positive patients attending a Nigerian tertiary hospital [24]
2016 Nigeria HIV infected patients 283 Framingham–lipid, 10 year risk &
Systematic Coronary Risk Evaluation
(SCORE)
The burden of hypertension, diabetes mellitus, and cardiovascular
risk factors among adult Malawians in HIV care: consequences for
integrated services [25]
2016 Malawi HIV infected patients 952 Framingham CVD risk and WHO/
ISH score
Distribution and performance of cardiovascular risk scores in a
mixed population of HIV-infected and community-based HIV-
uninfected individuals in Uganda [26]
2018 Uganda HIV infected and
Non-HIV infected
people
205 FRAM-BMI, FRAM lipids, Reynolds
risk score; ASCVD, D:A:D
Short-term and long-term cardiovascular risk, metabolic
syndrome and HIV in Tanzania. [27]




Metabolic disorders and cardiovascular risk in treatment-naive
HIV-infected patients of sub Saharan origin starting antiretroviral:





245 10 tear risk of WHO/ISH, FRAM-
lipids,D:A:D,
D:A:D—Data collection on Adverse effects of anti-HIV Drugs.
https://doi.org/10.1371/journal.pone.0243552.t002
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Of the 966 patients, 601 (62.2%) were women, the median age was 45 (IQR: 40–54) years,
246 (25.5%) had a diagnosis of hypertension, of which 220 (89.4%) were on anti-hypertensive
treatment: 30 (3.1%) had diabetes. Smoking history included 195 (20.2%) ex-smokers and 23
(2.4%), current smokers. For ART history, 180 (18.6%) had ever used Protease Inhibitors (PIs)
for a median (IQR) duration of 5.4 (2.3–6.8) years. Only six (0.6%) were current users of aba-
cavir. For those still on first line the median (IQR) duration on Nucleoside Reverse Transcrip-
tase Inhibitors (NRTIs) was 9.6 (9.4–9.8) years. The median (IQR) CD4 count was 505 (362–
684) cells/μL; the median (IQR) HDL cholesterol and total cholesterol was 1.20 (IQR 0.98–
1.48) and 4.73 (IQR 4.08–5.40) mmol/L respectively, median (IQR) body mass index was 22.4
(19.8–25.4) Kg/m2, and the systolic BP 120 (IQR 110–130) mmHg.
Table 4 and supplementary Table 2 in S1 File show the application of all the main tools to
the ALT cohort. The 10 year generated scores showed both higher risk and wider range (per-
centage at risk of getting CVD over 10-year event across all scores has a median of 1.7–3.8%)
than the 5 year generated scores (percentage at risk of an event over 5 years across all scores
has a median 1.1–1.4%). The ASCVD and Framingham lipids scores show higher percentage
of participants at high risk, compared to Framingham BMI. Framingham lipids 5 years also
showed a higher percentage of PLHIV at CVD high risk compared to both D:A:D scores.
Fig 1 and Table 6 show a head-to-head comparison of full model D:A:D, (which is specific
to PLHIV) and Framingham 5 year. Of the 966, both models categorized 251 individuals as
low risk, 409 as moderate risk, 16 as high risk and 6 as very high risk (supplementary Table 2
in S1 File). The median (IQR) predicated 5-year CVD risk of the D:A:D and the Framingham
was 1.2% (0.7–2.1) and 1.4% (0.9–2.5) respectively (Table 4). A comparison of the 5-year risk
scores gave a level of agreement of 90.1% (PABAK = 0.76; 95% CI 0.74–0.79; p value<0.001).
Comparison of score results across the cohort. Cross-classification was mapped in a
contingency table (supplementary Table 2 in S1 File) with nine comparisons for 10-year
Table 3. Descriptive summary of ALT cohort cardiovascular risk factors at enrolment (after 10 years of ART).
n = 966 %
Sex, Female 601 62.2




Ever used protease inhibitors 180 18.6
Current use of Abacavir 7 0.7
Current use of antihypertensive treatment 220 22.8
HIV RNA >400 copies/ml, n (%)� 400copies/ml, n (%) 36 3.7
Median IQR
Age (years) 45 40–50
HDL cholesterol (mmol/L) 1.20 0.98–1.48
Total Cholesterol (mmol/L) 4.73 4.07–5.40
Body mass index (Kg/m2) 22.4 19.8–25.4
Duration on PI (years) 5.4 2.3–7.0
Duration on NNRTI(years) 9.6 9.4–9.8
Systolic BP(mmHg) 120 110–130
CD4 count at cohort 2 enrollment cell/μL 505 362–684
CD4 count (Pre-ART) cell/μL (range) 81 26–155
ALT cohort—ART Long Term Cohort.
https://doi.org/10.1371/journal.pone.0243552.t003
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prediction scores and two for 5-year prediction scores. The PABAK was used to determine
level of agreement between scores that included lipid analysis and scores with no lipid analysis
as presented in Tables 5 and 6. The paired comparisons yielded moderate to substantial level
of agreement for all the comparisons (Table 5). Table 6 compares HIV specific versus non-
Table 4. Median(IQR) Percentage Scores of cardio-vascular risk over 5 or 10 years, applied to the ALT cohort.
Score Prediction period (years) Median(IQR) Rating n(%) Median(IQR)
ASCVD–(%) 10 2.5(0.70–5.4) low 816(84.5) 1.7(0.5–3.8).
High/high 150(15.5) 11.9(9.4–16.2)
Fram-BMI– 10 year risk (%) 10 1.7(0.8–3.1) low 919(95.1) 1.6(0.7–2.9)
Moderate 36(3.7) 12.5(11.2–14.0)
High 11(1.1) 32.9(21.7–36.3)
Fram Lipids-10 year risk 10 3.8(2.1–7.7) low 801(82.9) 3.1(1.9–5.1)
Moderate 117(12.1) 13.0(11.3–15.1)
High 48(5.0) 27.0(22.6–36.7)
Fram-lipids-5 year risk(%) 5 1.4(0.9–2.5) low 310(32.1) 0.7(0.5–0.9)
Moderate 568(58.8) 1.8(1.3–2.6)
High 88(9.1) 6.7(5.6–8.3)
D:A:D reduced (%) 5 1.1(0.2–1.9) low 460(47.6) 0.6(0.4–0.8)
Moderate 472(48.9) 1.8(1.3–2.6)
High/very high 33(3.4) 6.8(6.0–8.6)
D:A:D with full model(%) 5 1.2(0.7–2.1) low 404(42.0) 0.6(0.5–0.9)
Moderate 526(54.7) 1.8(1.3–2.5)
High/very high 31(3.2) 7.0(5.9–8.7)
WHO with cholesterol 10 NA low 946(97.9) NA
Moderate 13(1.3)
High/ Very high 7(0.7)
ASCVD (Atherosclerotic Cardiovascular Disease) only allows for 2 levels of classification—low or moderate/ high/ very high.
BMI—Body Mass Index.
WHO—World Health Organization.
D:A:D—Data collection on Adverse effects of anti-HIV Drugs.
Fram-BMI Framingham CVD risk prediction score that used BMI instead of lipids.
Fram lipids Framingham CVD risk prediction score that used lipids instead of BMI.
https://doi.org/10.1371/journal.pone.0243552.t004
Fig 1. Classification of ALT cohort participants in CVD risk categories by Framingham (5 year) and full DAD
5-year risk equations.
https://doi.org/10.1371/journal.pone.0243552.g001
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HIV specific 5-year scores, which yielded moderate to substantial level of agreement for all the
paired comparisons.
Discussion
In this study, we have applied a variety of screening tools to a cohort of PLHIV in Uganda who
have been on ART for at least 10 years. We used screening tools used by researchers around
the continent and we found no statistical difference in the risk scores generated when compar-
ing the different tools applied to our population. Overall, the Ugandan ALT cohort has a
median score of 1.1–1.4% risk of a CVD event over 5 years and 1.7–2.5% risk of a CVD event
over 10 years. The strength of this study is that we undertook a review of all the tools used
prior to the analysis and applied multiple tools to the ALT cohort; this yielded very similar
results. This risk is similar to other cohorts in Africa [28]. There are an increasing number of
publications related to screening for cardiovascular disease in PLHIV in SSA [19–28], however
there are multiple screening tools used and there is no consensus about which is the best to
use. In summary, there are 3 main variations between the most commonly used tools. These
are 1) requirement for lipid results 2) length of prediction time (risk over 5 years and risk of 10
years) 3) HIV specific criteria and adjustments.
In resource limited settings, the major challenges to screening include capacity (training
and available time) of health care workers, and availability of laboratory testing mainly driven
by financial constraints. Particularly, lipid analysis specifically is costly (approximately US$11)
and not routinely available in most health centres. Therefore, we evaluated the screening tools
comparing non-lipid dependent tools and lipid dependent tools (Table 6). Despite the higher
estimated number of people with high risk if lipids were used, there was a high level of agree-
ment in risk classification of patients seen between generated scores including and not includ-
ing lipid profiles. This is reassuring for those who are screening for cardiovascular disease
without lipid availability, and either WHO or Fram-BMI would be suitable and straightfor-
ward to use. These both result in a 10-year prediction of CVD risk.
We also compared HIV specific tests (D:A:D full and D:A:D restricted—Table 6), which
give 5 year predictions and these were in statistical agreement with the Framingham- Lipid 5
Table 6. Level of agreement between HIV specific CVD risk equations and non-HIV specific equations as applied
to the ALT.
Fram-Lipids
Full D:A:D model 90.1% 0.76(0.74–0.79), <0.001
Reduced D:A:D model 89.4% 0.75(0.72–0.77), <0.001
Key Crude level of agreement.
PBAK 95% Confidence Interval of PABAK).
https://doi.org/10.1371/journal.pone.0243552.t006
Table 5. Level of agreement between CVD risk equations including blood testing for lipids and no lipid testing as applied to the ALT cohort.
Predicted 10-year CVD risk scores
Score Fram-Lipids ASCVD WHO with cholesterol
WHO with no cholesterol 90.1% 0.78(0.75–0.82),<0.001 86.5% 0.73(0.690.77),<0.001) 99.0% 0.98(0.97–0.99), <0.001
Fram-BMI 90.0% 0.78(0.74–0.81), <0.001 86.0% 0.72(0.67–0.76), <0.001 95.7%% 0.90(0.88–0.93),<0.001
Key Crude level of agreement.
PBAK (95% Confidence Interval of PBAK).
https://doi.org/10.1371/journal.pone.0243552.t005
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year score. D:A:D categorized more cohort participants as high risk (Fig 1), which is unsurpris-
ing as it is adjusting for extra risk associated with ART use. In a SSA setting, due to widespread
use of public health monitoring tools for HIV, ART history is likely to be widely available,
therefore a full D:A:D may be possible. Unfortunately, both 5-year tools required lipid analysis
and we did not find tools that adjusted for HIV and ART related factors, without need for a
laboratory lipid analysis. It would be helpful to have a resource limited D:A:D score that
removes need for lipids, but does factor in ART history. Additionally, development and
deployment low cost point of care lipid evaluation for low income settings should be an
urgent research priority.
A limitation of this study is that it is a cross sectional analysis of the tools, and we have not
yet reached a follow up point to assess validity of the tools. Therefore, we have only been able
to assess agreement between tools in use in this setting. Another limitation is a challenge in
comparing 5 year and 10 year scores, which causes a little confusion in comparisons, but we
have tried to address this by providing clarity in the tables. Another limitation is that the ALT
cohort was missing information on family history, which is key in some of the tools. This is
not specific to the ALT cohort, as generally in SSA death certification, cause of death assess-
ments, and post mortems are not common, so it is common that relatives do not know the
cause of death in their family members. Therefore, inclusion of this question in screening
tools may lead to underestimated or overestimated scores.
So far in the published literature on CVD screening in PLHIV in SSA, these screening tools
have been used for cross sectional analysis and have not yet been used for long-term follow
up of PLHIV. This is due to the relative paucity of long-term non-HIV related morbidity and
mortality data as compared to Europe and North America, due to the more recent availability
of ART in Africa. The ALT cohort, as well as others in the region, is approaching a five-year
follow up period and we will assess the accuracy of the scores against our 5-year outcomes.
However, as our cohort and others described are reasonably small, a pooled analysis of this
data would provide more statistical power.
Conclusion
Given the burden of HIV in Uganda, if 3.4% of the PLHIV population are at a high risk of a
CVD event, this will equate to around 48,000cardiovascular events in PLHIV in Uganda over the
next 5 years. As this risk is modifiable with lifestyle advice and treatment of risk factors such as
diabetes and hypertension, screening and patient education seems a sensible addition to routine
HIV care. Our analysis suggests that the most common screening tools globally may provide use-
ful information in our environment. However, generally in our resource-limited setting, use of
cardiovascular screening tools is severely restricted by availability of lipid test results and family
history information. Whilst we are hesitant to suggest development of new screening tools to add
to an already crowded field, it would seem prudent to consider an HIV related adjustment of
some of the more simple tools. We would encourage low cost lipid testing development or adjust-
ment of D:A:D to remove need inclusion of laboratory lipid testing or other tools to include ART
history. We suggest that some of these simple adaptions may be a pragmatic approach to improv-
ing sensitivity and ease of use in resource-limited settings. When our ALT cohort reaches five-
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